- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
NICE recommends Ikervis in final draft guidance
4 November 2015 • Author: Victoria White
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Ikervis (ciclosporin, Santen Pharmaceutical) for treating severe keratitis in adults with dry eye disease which has not improved despite treatment with artificial tears.
Dry eye disease is chronic inflammation of the eyes caused by reduced tear production or excessive tear evaporation. It can be triggered by a number of factors, including dry or air-conditioned environments, auto-immune diseases (such as rheumatoid arthritis, and lupus), and the adverse effects of some medications. Symptoms include irritation and redness in the eyes, blurred vision, and a sensation of grittiness or a foreign body in the eye. If left untreated, it can result in blindness in severe cases.
Ikervis reduces inflammation in dry eye disease
Ikervis works by reducing inflammation in dry eye disease. However, until the launch of Ikervis, there has been no topical preparation of ciclosporin licensed in the UK. Ikervis has a novel cationic nano-emulsion formulation to effectively deliver the anti-inflammatory potential of ciclosporin. With this recommendation from NICE, Ikervis provides an important new option for the treatment of patients in England and Wales who have not responded to tear substitutes. In October of this year the Scottish Medicines Consortium (SMC) determined that Ikervis should be made available to patients in Scotland.
Professor Carole Longson, Director of the Centre for Health Technology Evaluation at NICE said: “Severe dry eye disease is painful and can have a significant negative effect on day-to-day life for people with the condition. The company responded to the requests in the draft guidance for more information, and we are pleased, therefore, to be able to recommend ciclosporin for adults with severe dry eye disease in final draft guidance published today. I am sure this will be welcome news to patients and healthcare professionals alike.”
NICE expects to publish its final guidance in December 2015.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics